



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

## ***Table of Contents and List of Tables***

Copyright VENTURE PLANNING GROUP  
This material is confidential for use by our clients only  
and may not be reprinted or reproduced.

VPG Publications, Consulting, Clients ***www.VPGcorp.com***

VPG Market Research Reports ***www.VPGMarketResearch.com***

Partner Reports ***www.LeadingMarketResearch.com***

**VENTURE PLANNING GROUP** 1271 Avenue of the Americas, Suite 4300 New York, NY 10020  
Phone + 1 212 564 2838 Fax + 1 212 564 8133 ***reports@vpgcorp.com***

## Table of Contents

### I. Introduction

### II. OCCULT BLOOD Worldwide Market and Technology Overview

#### A. Occult Blood: Clinical Significance and Laboratory Practices

#### B. Instrumentation Review And Market Needs

1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series
4. Abbott Architect ci8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS2
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus

Table of Contents (continued)

- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy 500
- C. Current and Emerging Technologies
  - 1. Monoclonal and Polyclonal Antibodies
  - 2. Immunoassays
    - a. Technological Principle
    - b. Radioimmunoassay (RIA)
    - c. Enzyme Immunoassays (EIA)
      - Overview
      - ELISA
      - Immunofiltration
      - Particle-Membrane Capture Immunoassay
      - Enzyme Amplification
    - d. Fluorescent Immunoassays
    - e. Luminescence
      - Chemiluminescence
      - Bioluminescence
    - f. Latex Agglutination
    - g. Immunoprecipitation
    - H. Affinity Chromatography
    - e. Liposome Flow-Injection Immunoassay
  - 3. Molecular Diagnostics
    - a. Technology Overview
    - b. Amplification Methods
      - PCR
        - DAP-PCR
        - Immuno-PCR
        - QC-PCR
      - CAR
      - DNA
      - HPA
      - LCR
      - NASBA
      - QBR
      - SDA
      - 3 SR, and others

Table of Contents (continued)

4. *Chromosome Analysis*
    - a. *Chronic Myelogenous Leukemia (CML)*
    - b. *Acute Myeloid Leukemia (AML)*
    - c. *Acute Lymphoblastic Leukemia (ALL)*
    - d. *Malignant Lymphomas*  
*Lymphoid Malignancies*
    - e. *Chronic Lymphocytic Leukemia (CLL)*
    - f. *Solid Cancers*
    - g. *Chromosomal Translocation and Oncogenes*
  5. *Artificial Intelligence*
  6. *Flow Cytometry*
  7. *Two Dimensional Gel Electrophoresis (2-DGE)*
  8. *Biosensors*
  9. *Competing/Complementing Technologies*
    - a. *CT*
    - b. *MRI*
    - c. *NMR*
    - d. *PET*
    - e. *Photonics Spectroscopy*
- E. *Personal Testing*
- III. France: *Test Volume and Diagnostics Sales Forecast by Market Segment*
- IV. Germany: *Test Volume and Diagnostics Sales Forecast by Market Segment*
- V. Italy: *Test Volume and Diagnostics Sales Forecast by Market Segment*
- VI. Japan: *Test Volume and Diagnostics Sales Forecast by Market Segment*
- VII. Spain: *Test Volume and Diagnostics Sales Forecast by Market Segment*
- VIII. U.K.: *Test Volume and Diagnostics Sales Forecast by Market Segment*
- IX. U.S.A.: *Test Volume and Diagnostics Sales Forecast by Market Segment*

Table of Contents (continued)

X. Design Criteria for Decentralized Testing Products

XI. Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types of Distributors
  - 7. Market Segmentation Factor

XII. Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

XIII. Competitive Profiles

- Abbott
- AdnaGen
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- Cepheid
- Correlogic Systems

Table of Contents (continued)

- *Decode Genetics*
- *Diadexus*
- *Diagnocure*
- *Diasorin*
- *Eiken Chemical*
- *Elitech Group*
- *Enterix*
- *Enzo Biochem*
- *Epigenomics*
- *Exact Sciences*
- *Fujirebio*
- *Hologic/Gen-Probe*
- *Guided Therapeutics*
- *Kreatech*
- *Kyowa Medex*
- *Mackay Life Sciences*
- *Myriad Genetics*
- *OncoLab*
- *Ortho-Clinical Diagnostics*
- *Panacea Pharmaceuticals*
- *Polartech*
- *Polymedco*
- *PreMD*
- *Qiagen*
- *Quest Diagnostics*
- *Radiant Pharmaceuticals*
- *Roche*
- *Scienion*
- *Sequenom*
- *Siemens Healthcare*
- *Takara Bio*
- *Targeted Diagnostics & Therapeutics*
- *Thermo Fisher*
- *Tosoh*
- *Veridex*
- *Wako Pure Chemicals*
- *Wallac/PE*
- *Zila*

*OCCULT BLOOD: US, EUROPE, JAPAN  
Test Volume and Sales Forecasts by Country*

*List of Tables*

*Major Companies Developing or Marketing Occult Blood Tests*

*France*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*

*Germany*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*

*Italy*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*

*Japan*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*

*Spain*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*

*U.K.*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*

*U.S.A*

*Occult Blood Test Volume and Diagnostics Sales  
by Market Segment*